Platelet Rich Plasma in Treatment of Melasma
מילות מפתח
תַקצִיר
תיאור
Melasma is a pigmentary disorder that can be disfiguring and can cause to significant emotional stresses for sufferers, for which a universally effective treatment is still lacking. Platelet rich plasma is commonly used in dermatology and plastic surgery, especially for treating chronic wounds, ulcers, and burns. The most important contents of platelets are contained in the α-granules. Some of the bioactive substances present in the α-granules include platelet-derived growth factor, transforming growth factor -β1 and -β2epidermal growth factor, and mitogenic growth factors such as platelet-derived angiogenesis factor and fibrinogen.
transforming growth factor -β1 decreases melanogenesis via delayed extracellular signal-regulated kinase activation. The regression of melasma in a 27-years-old woman after injecting platelet rich plasma for skin rejuvenation was observed, but controlled clinical trials are still lacking to confirm this preliminary observation.
תאריכים
אומת לאחרונה: | 05/31/2018 |
הוגש לראשונה: | 10/06/2017 |
ההרשמה המשוערת הוגשה: | 10/06/2017 |
פורסם לראשונה: | 10/11/2017 |
העדכון האחרון הוגש: | 06/24/2018 |
עדכון אחרון פורסם: | 06/26/2018 |
תאריך תחילת לימוד בפועל: | 10/31/2017 |
תאריך סיום משוער משוער: | 11/30/2019 |
תאריך סיום משוער ללימודים: | 12/06/2019 |
מצב או מחלה
התערבות / טיפול
Biological: Platelet rich plasma
שלב
קבוצות זרועות
זְרוֹעַ | התערבות / טיפול |
---|---|
Experimental: Platelet rich plasma intradermal injection of 5 ml of autologous platelet rich plasma in the lesional skin of the face of 20 melasma patients every 4 weeks for 3 times | Biological: Platelet rich plasma 10 ml of blood will be drawn from the patients on an anticoagulant then it will be centrifuged to get platelet rich plasma that will be injected in the melasma lesions of the patients after its activation with calcium chloride. |
קריטריונים לזכאות
גילאים הזכאים ללימודים | 18 Years ל 18 Years |
מינים הזכאים ללימודים | All |
מקבל מתנדבים בריאים | כן |
קריטריונים | Inclusion Criteria: - patients with melasma 18 years old or more Exclusion Criteria: - Patients less than 18 years. - Pregnant females and females on oral contraceptive pills. - Patients with a history of hypertrophic scars or keloids. - Patients with recurrent herpes infection or with present cutaneous infection and those with facial cancer. - Patients with blood disorders and platelet abnormalities and chronic liver disease. - Patients using systemic chemotherapy, anticoagulation therapy and antiplatelet agents. |
תוֹצָאָה
מדדי תוצאות ראשוניים
1. clinical improvement of melasma [3 months]
אמצעי תוצאה משניים
1. evaluation of transforming growth factor beta expression in the melasma skin [3 months]